First AD

Second AD

Patrick Y. Wen, MD, is is the director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute; as well as a professor of neurology at Harvard Medical School

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss available data for plixorafenib in central nervous system tumors harboring BRAF V600 mutations from the FORTE trial.

The FORTE Trial: Data for Plixorafenib in BRAF V600+ CNS Tumors

Video Series

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Exploring the Role of BRAF Inhibition in Primary CNS Malignancies

OncLive News Network®

Current Treatment Standards in Primary CNS Malignancies

The Role of BRAF Inhibition in CNS Malignancies 

Detailing the Exploration of Plixorafenib in CNS Malignancies

Safety Considerations for BRAF Inhibition in CNS Malignancies

Ongoing Research in Primary CNS Malignancies